The cream of British biotech

Ageing populations and burgeoning middle classes spell long-term growth for the biotech industry, says professional stock picker David Pinniger. Here, he tips three British pharmas to buy now.

Each week a professional investor tells MoneyWeek where he'd put his money now. This week: David Pinniger, CFA, investment manager at the International Biotech Trust.

On the 28 October 1982, the US Food & Drug Administration approved Genentech/Lilly's Humulin diabetes treatment. It was the first approval of its type and since then several hundred more biotechnology-based drugs have been developed for patients with a range of serious life-threatening illnesses.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
Explore More